merck_and_co

MSD files Lantus biosimilar with FDA

pharmafile | August 8, 2016 | News story | Sales and Marketing FDA, Lantus, MK-1293, MSD, application, biosimilar 

MSD, known as Merck in the US and Canada, has filed a new drug application with the US Food and Drug Administration (FDA) for MK-1293, a biosimilar candidate for Sanofi’s Lantus (insulin glargine) in the treatment of type-1 and type-2 diabetes.

The regulatory submission includes results of two Phase III studies which directly compared it with Sanofi’s Lantus. In these trials, the biosimilar demonstrated non-inferiority in change from baseline average blood glucose measure A1c.

MSD made a similar submission to the European Medicines Agency late last year, with the application currently under review. MK-1293 was developed by MSD with partial funding by Samsung Bioepis.

Advertisement

Peter Stein, vice president of late development in diabetes at MSD, says: “The FDA acceptance of our follow-on biologic application is an important milestone, and brings us closer to offering another treatment option for people in the US with diabetes. We are proud of the significant contributions we have already made to helping people with type-2 diabetes, and with investigational MK-1293, we hope to expand our portfolio into insulin therapeutics and treatments for people with type-1 diabetes.”

Sean Murray

Related Content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …

Johnson & Johnson submits robotic surgical system for De Novo classification

Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …

The Gateway to Local Adoption Series

Latest content